Q32 Bio Inc. - Common Stock, par value $0.0001 per share (QTTB) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
QTTB on Nasdaq
Shares outstanding
14,522,867
Price per share
$3.93
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
8,043,846
Total reported value
$26,659,216
% of total 13F portfolios
0%
Share change
-384,630
Value change
-$1,063,038
Number of holders
51
Price from insider filings
$3.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Q32 Bio Inc. - Common Stock, par value $0.0001 per share (QTTB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.9% $8,085,220 2,057,308 Point72 Asset Management, L.P. 17 Feb 2026
Opaleye Management Inc. 8.6% $4,936,976 1,256,228 Opaleye Management Inc. 19 Feb 2026
PFIZER INC 2.3% $994,442 277,777 Pfizer Inc. (IRS Identification No.: 13-5315170) 31 Dec 2024
BRISTOL MYERS SQUIBB CO 1.6% $312,381 200,244 BRISTOL MYERS SQUIBB CO 31 Dec 2024

As of 31 Dec 2025, 51 institutional investors reported holding 8,043,846 shares of Q32 Bio Inc. - Common Stock, par value $0.0001 per share (QTTB). This represents 55% of the company’s total 14,522,867 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Q32 Bio Inc. - Common Stock, par value $0.0001 per share (QTTB) together control 55% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 16% 2,252,987 0% 0.16% $7,479,917
Atlas Venture Life Science Advisors, LLC 14% 2,092,106 0% 0.8% $6,945,792
Carlyle Group Inc. 7.6% 1,102,741 0% 0.03% $3,616,990
ACORN CAPITAL ADVISORS, LLC 3.4% 493,425 -39% 0.56% $1,638,171
VANGUARD GROUP INC 2.2% 321,051 +8.7% 0% $1,065,889
ARCH Venture Management, LLC 2.2% 320,482 0% 0.16% $1,064,000
Pfizer Inc 1.9% 277,777 0% 0.39% $922,220
Sanofi 1.7% 244,083 0% 0.26% $810,356
Opaleye Management Inc. 1.5% 213,363 0.09% $708,365
GEODE CAPITAL MANAGEMENT, LLC 0.73% 106,113 +20% 0% $352,395
RENAISSANCE TECHNOLOGIES LLC 0.69% 99,600 +111% 0% $330,672
BlackRock, Inc. 0.41% 59,932 -36% 0% $198,974
MILLENNIUM MANAGEMENT LLC 0.35% 51,268 -51% 0% $170,210
Monaco Asset Management SAM 0.35% 50,919 -84% 0.05% $169,051
ACADIAN ASSET MANAGEMENT LLC 0.33% 48,373 +63% 0% $159,000
TWO SIGMA INVESTMENTS, LP 0.32% 46,825 +49% 0% $155,459
CITADEL ADVISORS LLC 0.31% 45,728 +352% 0% $151,817
Affinity Asset Advisors, LLC 0.19% 27,777 0% 0.01% $92,220
JANE STREET GROUP, LLC 0.17% 25,374 0% $84,242
NORTHERN TRUST CORP 0.17% 25,033 -22% 0% $83,110
HRT FINANCIAL LP 0.17% 24,698 +66% 0% $81,000
STATE STREET CORP 0.15% 21,237 0% 0% $70,507
XTX Topco Ltd 0.14% 20,353 0% $67,572
ADAR1 Capital Management, LLC 0.14% 20,000 0% $66,400
Scientech Research LLC 0.11% 15,510 0.03% $51,493

Institutional Holders of Q32 Bio Inc. - Common Stock, par value $0.0001 per share (QTTB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 8,043,846 $26,659,216 -$1,063,038 $3.32 51
2025 Q3 8,428,600 $16,632,224 -$986,752 $1.98 52
2025 Q2 8,978,370 $13,355,302 -$657,201 $1.49 59
2025 Q1 9,406,123 $15,511,257 -$5,227,234 $1.65 71
2024 Q4 10,994,953 $37,808,803 -$51,251,129 $3.44 88
2024 Q3 9,108,413 $405,845,227 +$55,628,540 $44.62 71
2024 Q2 8,065,328 $144,178,979 +$11,388,677 $17.95 54
2024 Q1 7,430,290 $125,894,701 +$125,894,701 $17.04 38